| __timestamp | Amneal Pharmaceuticals, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 335989000 | 9335772 |
| Thursday, January 1, 2015 | 367054000 | 999000 |
| Friday, January 1, 2016 | 420770000 | 978000 |
| Sunday, January 1, 2017 | 507476000 | 952000 |
| Monday, January 1, 2018 | 946588000 | 956000 |
| Tuesday, January 1, 2019 | 1273376000 | 8122999 |
| Wednesday, January 1, 2020 | 1364130000 | 8712000 |
| Friday, January 1, 2021 | 1324696000 | 13980000 |
| Saturday, January 1, 2022 | 1427596000 | 21135000 |
| Sunday, January 1, 2023 | 1573042000 | 10755000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, understanding cost dynamics is crucial. Amneal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. present a fascinating contrast in their cost of revenue from 2014 to 2023. Amneal's cost of revenue has surged by approximately 368%, reflecting its expansive growth and market penetration. In contrast, Iovance's costs have remained relatively stable, with a modest increase of around 15% over the same period. This disparity highlights Amneal's aggressive scaling strategy compared to Iovance's steady, research-focused approach. Notably, Amneal's costs peaked in 2023, reaching nearly 1.6 billion, while Iovance's highest was just over 21 million in 2022. This data underscores the diverse strategies within the biopharmaceutical sector, where growth and innovation drive financial outcomes. As the industry evolves, these insights offer a glimpse into the strategic decisions shaping the future of healthcare.
Comparing Cost of Revenue Efficiency: AbbVie Inc. vs Amneal Pharmaceuticals, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Amneal Pharmaceuticals, Inc.
Cost of Revenue Comparison: Biogen Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Amneal Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Insmed Incorporated and Amneal Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Iovance Biotherapeutics, Inc.
Cost of Revenue Trends: Lantheus Holdings, Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Cytokinetics, Incorporated vs Amneal Pharmaceuticals, Inc.
Cost Insights: Breaking Down Ionis Pharmaceuticals, Inc. and Amneal Pharmaceuticals, Inc.'s Expenses
Analyzing Cost of Revenue: Amneal Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated
Iovance Biotherapeutics, Inc. vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored